by Neutralizing antibodies have generated significant interest as a promising therapeutic approach against various infectious diseases. Neutralizing antibodies bind to pathogens such as viruses and prevent them from infecting host cells. The neutralizing antibody market includes monoclonal antibodies that bind to the spike protein of SARS-CoV-2, rendering the virus unable to infect human cells. These antibodies mimic the body’s immune response to infections and help cut the duration of illness. Major biopharmaceutical players are focusing on developing monoclonal antibody therapies for the treatment and prevention of COVID-19.
The global neutralizing antibody market is estimated to be valued at US$ 1.87 billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Adoption as a Promising Medical Treatment Against COVID-19 Pandemic (as mentioned in the heading) has emerged as a key driver of the neutralizing antibody market. Neutralizing antibodies offer several advantages over vaccines for COVID-19 such as immediate immunization without the need to wait for the body’s natural immune response to develop. Another major driver is the surge in R&D investments by pharmaceutical companies to develop monoclonal antibody therapies against SARS-CoV-2. For instance, in February 2022, Eli Lilly received an emergency use authorization from the FDA for bebtelovimab, a monoclonal antibody for the treatment of mild-to-moderate COVID-19. Large clinical trials are ongoing to demonstrate the safety and efficacy of various antibody drug candidates.
Segment Analysis
The neutralizing antibody market can be segmented into product and application. The product segment includes humanized neutralizing monoclonal antibodies, human neutralizing monoclonal antibodies, and mouse neutralizing monoclonal antibodies. The humanized neutralizing monoclonal antibodies segment dominates the market and is expected to grow at the fastest rate over the forecast period. This is because humanized monoclonal antibodies have fewer side effects on humans as they are derived from both human as well as mouse cell lines.
PEST Analysis
Political: Regulations regarding approval of neutralizing monoclonal antibodies vary across countries. Stringent regulatory norms may hamper market growth.
Economic: Rising healthcare expenditure, increasing funding for R&D of novel therapeutics, and growing demand for monoclonal antibody drugs are fueling market growth.
Social: Increasing cases of chronic and infectious diseases, rising awareness about the benefits of targeted therapy are positively impacting the market.
Technological: Advancements in monoclonal antibody engineering technologies, development of antibody drug conjugates and bispecific antibodies offer lucrative opportunities.
Key Takeaways
Global Neutralizing Antibody Market Size is estimated to be valued at US$ 1.87 Billion in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2031.
Regional analysis
North America dominates the neutralizing antibody market currently. This is attributed to presence of major players, high healthcare spending, and growing usage of monoclonal antibodies for treatment of various diseases in the US and Canada. Asia Pacific is expected to witness the fastest growth during the forecast period owing to rising healthcare expenditure, increasing government initiatives to modernize healthcare infrastructure, and growing research activities in emerging countries.
Key players
Key players operating in the neutralizing antibody market are Mohawk, Regeneron, Vir Biotechnology, WuXi Biologics, Adagio Therapeutics. Mohawk and Regeneron are currently dominating the market owing to their robust R&D capabilities and diverse product portfolios.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
